Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine

A technology for serum thymus factor and chemotherapeutic drugs, which is applied in the field of application of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physics and chemotherapeutic drugs

Inactive Publication Date: 2008-07-30
中国生化制药工业协会
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there are no patents and research reports on the application of FTS as an anti-tumor and immune-enhancing drug at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine
  • Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine
  • Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] This embodiment relates to the results of the EAC ascites tumor group

[0052] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model mice were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the doses were 0.25 mg·kg -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; the positive drug group, 5-fluorouracil, once every other day, three times in total. The results are shown in Table 1:

[0053] Table 1 The results of FTS for anti-EAC ascites tumor drugs (x±s, n=10)

[0054] group

Survival time (days)

life extension rate

high dose

medium dose

low dose

positive control

blank control

18.3±3...

Embodiment 2

[0058] This example relates to the results of the H22 solid tumor group

[0059] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model mice were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the doses were 0.25 mg·kg -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide administered once. The results are shown in Table 2.

[0060] Table 2 The results of FTS for anti-H22 solid tumor drugs (x±s, n=10)

[0061] group

Weight of solid tumor (g)

Tumor inhibition rate

high dose

medium dose

low dose

positive control

blank control

2.5±0.9 △△

2.7±0.7 △△

3.1±1.4

0.6±0.5 ...

Embodiment 3

[0065] This embodiment relates to the results of the Walker-256 tumor group

[0066] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model rats were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the dose was 2.2 mg·kg -1 , medium dose 1.1mg·kg -1 , low dose 0.55mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide administered once. The results are shown in Table 3.

[0067] The next day after the last administration in the treatment group, the solid tumors were dissected out and weighed, and the tumor inhibition rate was calculated. The tumor inhibition rates of the administration groups were all greater than 30%, and there was a quantitative-effect relationship, and the cura...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses applications of serum thymus factor (FTS) in preparation of anti-tumor medicines, protective medicine or immunity intensified medicines for physical treatment and chemical treatment of tumor. Experimental results reveal that all groups of tumor-bearing mice and W256 rat fed with medicines are significantly different from groups fed with physiological saline and the tumor inhibition rates of all the groups fed with the medicines are more than 30 percent, thus confirming the tumor inhibition effect of the FTS. The FTS can also enhance the immunity activity and strengthen the immunity function of living organisms in a plurality of aspects; the FTS has no toxicity and less side effects; the effective wide dose scope and wide safety range. The FTS has obvious protective function to immunity indexes of living organisms, which is discovered in the study of the protective medicines for the physical and chemical treatment medicines of tumor. Therefore, the FTS can provide a new target and development for the clinical treatment of tumor.

Description

technical field [0001] The invention relates to a new application of biochemical substances in pharmaceutical engineering, more specifically the application of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs or immune-enhancing drugs. Background technique [0002] Cancer is one of the main causes of human death. According to the statistics of the World Health Organization, there are about 5 million patients who die of cancer every year in the world. In recent years, due to the deterioration of our living environment, the incidence of cancer has increased, and there is a trend of younger patients. It can be seen that the prevention and treatment of cancer is very urgent. Drug therapy is one of the main treatments for cancer. Over the past century, remarkable achievements have been made in the drug treatment of cancer, and dozens of anti-tumor drugs have been developed, which effectively prolong the l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61P35/00
Inventor 徐康森乐嘉静廖晓泉王悦张长平李湛君
Owner 中国生化制药工业协会
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com